Nkarta (NKTX) Non Operating Income (2019 - 2026)
Nkarta's quarterly Non Operating Income came in at $3.0 million in Q1 2026, down 33.55% year-on-year from $4.6 million in Q1 2025, and down 80.67% quarter-over-quarter from $15.8 million in Q4 2025.
Nkarta has reported Non Operating Income for 8 years, with the latest figure at $3.0 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 33.55% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $24.6 million (down 16.43% YoY), and the FY2025 full-year result was $17.9 million, down 7.68% from the prior year.
- Non Operating Income for Q1 2026 stood at $3.0 million, down from $15.8 million in the prior quarter.
- The five-year high for Non Operating Income was $19.4 million in Q4 2024, with the low at -$2000.0 in Q1 2024.
- Average Non Operating Income over 5 years is $4.5 million, with a median of $3.5 million recorded in 2023.
- Year-over-year, Non Operating Income plunged 100.93% in 2022 and jumped 349900.0% in 2023.
- Tracing NKTX's Non Operating Income over 5 years: stood at $5.1 million in 2022, then sank by 32.71% to $3.4 million in 2023, then soared by 465.75% to $19.4 million in 2024, then fell by 18.86% to $15.8 million in 2025, then slumped by 80.67% to $3.0 million in 2026.
- The last three Non Operating Income figures came in at $3.0 million (Q1 2026), $15.8 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 3.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.04 Mn |
| Dec 31, 2025 | 15.75 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Jun 30, 2025 | 239,000.00 |
| Mar 31, 2025 | 4.58 Mn |
| Dec 31, 2024 | 19.41 Mn |
| Sep 30, 2024 | 5.45 Mn |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | 3.43 Mn |
| Sep 30, 2023 | 3.65 Mn |
| Jun 30, 2023 | 3.57 Mn |
| Mar 31, 2023 | 3.50 Mn |
| Dec 31, 2022 | 5.10 Mn |
| Sep 30, 2022 | 1.92 Mn |
| Jun 30, 2022 | 689,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Dec 31, 2021 | -2,000.00 |
| Sep 30, 2021 | -6,000.00 |
| Jun 30, 2021 | -5,000.00 |
| Mar 31, 2021 | 108,000.00 |
| Dec 31, 2020 | 39.95 Mn |
| Sep 30, 2020 | -153,000.00 |
| Jun 30, 2020 | 4,000.00 |
| Mar 31, 2020 | 702,000.00 |
| Dec 31, 2019 | -3.09 Mn |
| Sep 30, 2019 | 35,000.00 |
| Jun 30, 2019 | -167,133.00 |